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Letter to the editor
Intestinal microsporidiosis in a reference center
Dear Editor,
In the last two decades, the scientific community has recog-
nized the Microsporidia importance and associated it with
serious infections in immunocompromised patients.1 Since
its discovery in 1857, there was controversies in its phyloge-
netic classification, being recently classified as fungi.1,2 There
have been described 150 genera and over 1300 species. Eight
genera are described in human hosts: Enterocytozoon, Encephal-
itozzon, Pleistophora, Trachipleistophora, Vittaforma, Brachiola,
Nosema, and Microsporidium. Fourteen species are associated
with human diseases, including Enterocytozoon bieneusi and
Encephalitozoon intestinalis. Microsporidia causes systemic and
non-systemic diseases, with wide spectrum of clinical mani-
festation, principally chronic diarrhea.3
As little is known about microsporidia and its importance
as infectious agent in immunocompromised patients, we con-
ducted a retrospective study in 347 stool samples analyzed for
the presence of microsporidiosis to describe the associated
underlying diseases. The data were registered in the Para-
sitology Laboratory of UNICAMP (2011–2012). All patients for
whom there was a medical request to exam the stools for the
presence of microsporidia were included. Patients’ underlying
disease was recorded.
Out of the 347 [210 (60.52%) males] fecal samples analyzed,
140 (40.34%) were positive for microsporidia. The majority of
the positive samples came from male patients [94 (67.14%)].
Table 1 – Microsporidia identification related to clinical status.
Groups n Positive cases % (related to groups) % (related to all patients) OR (95% CI)
HIV+/AIDS 120 51 42.50% 14.70% 1.146 (0.729–1.797)
Transplantion 100 42 42% 12.02% 1.101 (0.684–1.765)
Gastric diseases 28 9 32.14% 2.63% 0.681 (0.285–1.536)
Renal diseases 26 11 42.30% 3.19% 1.091 (0.472–2.465)
Liver diseases 25 6 24.0% 1.73% 0.444 (0.158–1.109)
Neoplasia 10 3 30.0% 0.87% 0.444 (0.158–1.109)
Lupus 8 4 20.0% 1.15% 0.6265 (0.129–2.428)
Tuberculosis 6 5 83.33% 1.45% 1.491 (0.331–6.713)
Cystic fibrosis 3 0 0% 0% –
Others 21 9 42.85% 2.60% 1.116 (0.441–2.751)
Total 347 140 – 40.34%
n, number of patients; %, percentage; OR, odds ratio; CI, confidence interval.
Table 1 shows the underlying diseases of patients found
with microsporidia in their feces. The positivity rates were
75% (75/100), 22% (22/100), and 3% (3/100) among those who
underwent bone marrow, kidney and liver transplantation,
respectively.
The underlying diseases of the positive cases were diar-
rhea (eight), Crohn’s disease (one), leukemia (one), lymphoma
(two), chronic renal failure (two), nephritic syndrome (two),
end-stage renal disease (five), cirrhosis (six), pulmonary dis-
ease (two), immunodeficiency (1), and none (5).
Microsporidiosis is a cosmopolitan disease whose preva-
lence haswide variability depending on the geographic region,
population studied and diagnostic methods.4 Immunocom-
promised patients aremore affected by seriousmicrosporidio-
sis, especially HIV-patients. In the early ‘80s, before the AIDS
epidemic, microsporidiosis was rarely described in humans.
Since 1990, the prevalence of HIV-associated microsporidia
infection has been reported to range from 1.5 to 50%.3 Trans-
planted patients are another risk group for microsporidiosis.5
The wide spectrum of clinical manifestations depends
on the species, site of infection and host immunity.4 Gas-
trointestinal microsporidiosis is predominantly observed in
HIV-patients, especially with advanced immunosuppression.1
Asymptomatic microsporidiosis has been described in
immunocompetent, as well as in immunocompromised
patients. The search for microsporidia in fecal samples should
be performed in immunocompromised patients, even without
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symptoms, not only due to the risk of overt symptoms, but also
because of the significant transmission risk.1
In conclusion, high positivity for microsporidiosis was
observed among HIV-infected patients and transplant recip-
ients, highlighting the importance of early diagnosis and
implementation of measures for disease prevention.
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